About this trial
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Eligibility criteria
Qualifiers
pathologically or cytologically metastatic or locally advanced cancer
anorexia and >=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia >=5
ECOG performance status 0-3
able to complete questionaire and able to swallow pills
Disqualifiers
receiving chemotherapy or anti-cancer systemic therapy
life expectancy longer than 1 month
received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
surgery within 4 weeks
Trial design
Treatments tested in this trial
- Olanzapine 2.5 MG
- Olanzapine 5 MG
- Placebo